Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

Radiopharmaceuticals Market: Introduction

According to the report, the global radiopharmaceuticals market was valued at US$ 3.9 Bn in 2020 and is projected to expand at a CAGR of 7.3% from 2021 to 2031. The market declined in 2020 due to COVID-19 outbreak. Radiopharmaceuticals include a group of radioactive agents used for either diagnostic or therapeutic interventions. Radiopharmaceuticals compounds used for diagnostic interventions usually either emit beta particles (positrons or electrons) or gamma rays, while compounds that emit Auger electrons or alpha particles are used generally for therapeutic interventions. When radiopharmaceuticals are used for diagnostic purposes, the drugs are known as “tracers.” Diagnostic radiopharmaceuticals contain smaller amounts of radiation than those used for treatment.

Increase in Application of Radiopharmaceuticals Compounds as Imaging Agents in Non-oncology Conditions to Drive Market

Clinical applications of positron emission tomography/computed tomography (PET-CT) with the glucose analogue 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) radiopharmaceuticals compound are spreading beyond oncology. Apart from its high usage in clinical oncology, FDG PET-CT is widely used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience. In several centers, cardiac FDG PET is becoming the gold standard for assessment of myocardial viability. In patients with cardiac sarcoidosis, FDG PET has proven useful as a follow-up tool for disease monitoring. This is likely to drive the global market.

Request a PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213

Technetium-99m to Dominate Global Market

The global radiopharmaceuticals market has been segmented based on compound, indication, system, and end-user. In terms of compound, the global radiopharmaceuticals market has been classified into fluorine-18 derivatives, tc-99, Lu-177, Ga-68, Zr-89, 11C-choline, 14C-urea, and others. The tc-99 segment is anticipated to account for major share of the global market by 2031 due to lower price and easy production process. Moreover, the compound is suitable for imaging the thyroid, lacrimal glands, vascular perfusion, pulmonary perfusion, bones, myocardial, etc.

Oncology to be Key Indication

Based on indication, the global radiopharmaceuticals market has been categorized into oncology, neurology, cardiology, and others. The oncology segment is expected to expand at a high CAGR during the forecast period due to increase in demand for radiopharmaceuticals agents for better treatment access in oncology across the globe.

Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=213

Hospitals to be Major End User

In terms of end-user, the global radiopharmaceuticals market has been divided into hospitals, diagnostic labs, and others. The hospitals segment is expected to expand at a high CAGR during the forecast period due to increase in demand for installation of new PET-CT machines in the upcoming hospital projects across the globe.

North America to Lead Global Market

The global radiopharmaceuticals market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World. North America dominated the global radiopharmaceuticals market in 2020, followed by Europe. North America accounted for major share of the global radiopharmaceuticals market in 2020, due to rise in installations of PET-CT scanner device and increase in demand for disease risk assessment services for oncology treatment. The radiopharmaceuticals market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are projected to drive the radiopharmaceuticals market in the region.

Buy Radiopharmaceuticals Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=213&ltype=S

Competition Landscape

The report also presents profiles of leading players in the global radiopharmaceuticals market. These include Siemens Healthineers, GE Healthcare, Advanced Accelerator Applications (a Novartis AG Company), Jubilant Pharma Limited, Bayer AG, ITM Isotopen Technologien München AG, Telix Pharmaceuticals, Lantheus Holdings, Inc., Eli Lilly and Company, Nihon Medi-Physics, and Avanos Medical, Inc.

Leading companies in the global radiopharmaceuticals market focus on strengthening the distribution network and expanding product range & applications to gain market share. For instance, in January 2018, Advanced Accelerator Applications received the U.S. FDA approval for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Mr. Rohit Bhisey

Transparency Market Research

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Blog: https://tmrblog.com/

Follow UsTwitter | LinkedIn

Press Release Source: https://www.transparencymarketresearch.com/pressrelease/radiopharmaceuticals-market.htm

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts